Compare Johnson & Johnson (JNJ) vs Unilever plc (UL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Unilever plc — how do they compare? Johnson & Johnson trades at $256.22 (market cap $618.09B), while Unilever plc trades at $61.66 (market cap $131.63B). The key difference: Johnson & Johnson is far larger — about 4.7× Unilever plc's market cap, and Unilever plc pays the higher dividend (3.43%). Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Unilever plc for 112 Days on average.
| JNJ | UL | |
|---|---|---|
Market Cap | $618.09B | $131.63B |
Volume | 6,050,983 | 2,978,741 |
Sector | Health | Consumer Staples |
52-Week High | $278.43 | $74.59 |
52-Week Low | $186.00 | $55.05 |
Typical Hold Time | 129 Days | 112 Days |
Enterprise Value | $646.37B | $156.65B |
Dividend Yield | 2.09% | 3.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $258.45, up 1.44% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $94.19B revenue, 21.48% net margin, and robust cash flow. Analyst consensus is bullish with a $286.53 price target, though technical indicators show resistance near $260. Recent news highlights pipeline strength including Icotyde's potential $4.5B peak sales.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and competitive pressures. The stock presents value near current levels with 10.7% upside to consensus target, though technical weakness suggests potential near-term consolidation. Long-term growth drivers include oncology portfolio and Ottava surgical system development.
Unilever (UL) trades at $60.98, up 0.3% on the day, amid a bearish technical outlook and mixed financial performance. Revenue declined to $50.50 billion in 2025, though net income improved to $9.47 billion, with a high net margin of 18.74%. Recent earnings have consistently missed expectations, while the company is streamlining its portfolio through a planned food business merger with McCormick, facing regulatory scrutiny.
The stock presents a cautious outlook with strong profitability metrics like a 54.56% ROE offset by valuation concerns (P/E of 21.59) and earnings misses. Risks include integration challenges from the McCormick deal and competitive pressures, but its focus on beauty and personal care offers growth potential in emerging markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Unilever plc
Unilever is a diversified personal product (42% of 2021 sales by value), home care (20%), and packaged food (38%) company. Its brands include Knorr soups and sauces, Hellmann's mayonnaise, Lipton teas, Axe and Dove skin products, and the TRESemme haircare brand. The firm has been acquisitive in recent years
Read more on UL →
